Genmab — Juli 2024
-
-
Jnj sagde her i foråret at de så estimaterne for Tecvayli 25% højere end Wall Street generelt. Og at de så det dobbelte af WS for Talvey. Jnj estimerede begge til 5 mia foreløbig. Kan bl.a ses her https://www.fiercepharma.com/pharma/jpm24-johnson-johnson-ceo-says-tecvayli-talvey-and-several-other-meds-can-vastly-outperform
-
-
Roche YTD June 2024 Lunsumio CHF37mn Columvi CHF 67mn (Q1 '24 Lunsumio CHF16mn Columvi CHF 25mn) https://assets.roche.com/f/176343/x/ca635dfd8b/240725_ir_hy.pdf https://assets.roche.com/f/176343/x/26b92ed3d9/irp240725-a.pdf
-
also, Ocrevus 3,359mn YTD, not growing much atm, but that may change again with SC dosing https://x.com/Biotech2050/status/1816360745887752508/photo/2
-
Kort video: Sommerpanik på aktiemarkederne https://proinvestor.com/boards/121481
-
Genmabs kræfthåb viser fortsat solide vækstrater https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater
-
ADS i usa stiger med 1% - svarende til den danske notering..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind